




MTRSPALLLLLLGALPSAEAARGPPRMADKVVPRQVARLGRTVRLQCPVEGDPPPLTMWT	60
KDGRTIHSGWSRFRVLPQGLKVKEVEAEDAGVYVCKATNGFGSLSVNYTLIIMDDISPGK	120
ESPGPGGSSGGQEDPASQQWARPRFTQPSKMRRRVIARPVGSSVRLKCVASGHPRPDIMW	180
MKDDQTLTHLEASEHRKKKWTLSLKNLKPEDSGKYTCRVSNKAGAINATYKVDVIQRTRS	240
KPVLTGTHPVNTTVDFGGTTSFQCKVRSDVKPVIQWLKRVEYGSEGRHNSTIDVGGQKFV	300
VLPTGDVWSRPDGSYLNKLLISRARQDDAGMYICLGANTMGYSFRSAFLTVLPDPKPPGP	360
PMASSSSTSLPWPVVIGIPAGAVFILGTVLLWLCQTKKKPCAPASTLPVPGHRPPGTSR	420
ERSGDKDLPSLAVGICEEHGSAMAPQHILASGSTAGPKLYPKLYTDVHTHTHTHTCTHTL	480
SCGGQGSSTPACPLSVLNTANLQALCPEVGIWGPRQQVGRIENNGGRVS	529












10.00 1.00 -FGFR5β -FGFR5γ -FGFR2 MTS Conversion (Mean OD +/- SD)


Concentration (nM)



A

$\textbf{FGFR5}\beta\textbf{-treated PBMC}$


Overlay Plot 1



B


FGFR5γ -treated PBMC

Overlay Plot 2



MTPSPLLLLLPPLLLGAFPPAAAARGPPKMADKVVPRQVARLGRTVRLQCPVEGDPPPL	60
TMWTKDGRTIHSGWSRFRVLPQGLKVKQVEREDAGVYVCKATNGFGSLSVNYTLVVLDDI	120
SPGKESLGPDSSSGGQEDPASQQW <i>ARPRFTQPS<mark>KMRRRVIARPV</mark></i> GSSVRLKCVASGHPRP	180
DITWMKDDQALTRPEAAEPRKKKWTLSLKNLRPEDSGKYTCRVSNRAGAINATYKVDVIQ	240
RTRSKPVLTGTHPVNTTVDFGGTTSFQCKVRSDVKPVIQWLKRVEYGAEGRHNSTIDVGG	300
OKFVVLPTGDVWSRPDGSYLNKPL	324

Figure 11



120

100

PBMC + anti-CD3

Adherent Cells

120

100

80

9

(Im\gn) M9O

Media

LPS

FGFR2

FGFR5

LPS

FGFR5 FGFR2

20


40

9


(Im\gn) N9O


20

Figure 12




B FGFR5 Induced Proliferation of non-adherent BMCs





FGFR5 Induces the Proliferation of BM Stromal Cells



Effect of FGFR5 on 6AVS cell proliferation






Figure 15

Treatment





Effect of FGFR5 on CFU-pre-B formation from BMCs




Figure 17

fMLP Induces the Secretion of FGFR5 from PMN




Figure 18

PMA, TNF α and IL-2 Induce FGFR5 Secretion by PMN




Figure 19

.




Figure 20




Figure 21






Figure 22



-mAb 15G6 (monomeric/CD3) -B-mAb 15G6 (monomeric) ——— mAb 15G6 (CD3) → mAb 15G6 100.00 10.00 Antibody Concentration (nM) 1.00 Co-Stimulant Alone 0.10 Media Alone H 0.01 0 120000 100000 80000 00009 40000 20000 Counts Per Minute (CPM)

--- mAb 15G6 (FGFR5B/CD3) -A- mAb 15G6 (FGFR5B) —△— mAb 15G6 (CD3) - mAb 15G6 100.00 10.00 Concentration (nM) 1.00 Co-Stimulant Alone A 0.10 Media Alone 0.01 100000 120000 80000 20000 00009 40000 Counts Per Minute (CPM)

Figure 25



100.00 10.00 0.10 1.00 1U.U Sample Concentration (nM) Figure 26 5G6/FGFR5B-Fc FGFR5B-Fc -mAb 1 ⊕ mlgG/ Co-Stimulant Media Alone Alone 0.01 2.0 0.0 2.4

Figure 27




Figure 28

